VKH
HRTX icon

Virtu KCG Holdings’s Heron Therapeutics HRTX Stock Holding History

Virtu KCG Holdings’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$347K Buy
25,053
+9,637
+63% +$140K 0.01% 1503
2017
Q1 		$231K Sell
15,416
-14,846
-49% -$205K 0.01% 2270
2016
Q4 		$396K Buy
+30,262
New +$475K 0.01% 1782
2015
Q2 		– Sell
-10,015
Closed -$146K – 3501
2015
Q1 		$146K Buy
+10,015
New +$113K ﹤0.01% 2537

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu KCG Holdings's HRTX Position: Q2 2017 in Review

Virtu KCG Holdings increased its Heron Therapeutics (HRTX) stake by 63% in Q2 2017, buying an estimated $140K and bringing the position to 25,053 shares worth $347K. The position accounts for 0.01% of the portfolio, ranked #1503.

Virtu KCG Holdings first reported a position in HRTX in Q1 2015 and has held it in 4 quarters since. The position peaked at $396K in Q4 2016. 104 funds tracked by Wall St. Rank hold HRTX as of Q2 2017.

  • Virtu KCG Holdings held 25,053 shares of Heron Therapeutics worth $347K as of Q2 2017.
  • Virtu KCG Holdings bought 9,637 Heron Therapeutics shares in Q2 2017, an estimated $140K.
  • Heron Therapeutics made up 0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #1503 holding.
  • Virtu KCG Holdings first reported a position in Heron Therapeutics in Q1 2015 and has held it in 4 quarters since.
  • Virtu KCG Holdings's Heron Therapeutics position peaked at $396K in Q4 2016.
  • 104 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.